3-(10,11-Dihydro-5H-dibenzo(a,d)-cyclohepten-5-yliden)-N,N-dime-thyl-1-propanamin-hydrochlorid

This chemical does not meet GHS hazard criteria for 0.7% (1 of 136) of reports.

Danger

H301 (71.3%): Toxic if swallowed [Danger Acute toxicity, oral]；H302 (27.9%): Harmful if swallowed [Warning Acute toxicity, oral]；H318 (27.2%): Causes serious eye damage [Danger Serious eye damage/eye irritation]；H319 (35.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]；H361 (25.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]；H361d (13.2%): Suspected of damaging the unborn child [Warning Reproductive toxicity]；H362 (26.5%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]；H370 (40.4%): Causes damage to organs [Danger Specific target organ toxicity, single exposure]；H400 (72.1%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]；H410 (72.8%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]

P203, P260, P263, P264, P264+P265, P270, P273, P280, P301+P316, P301+P317, P305+P351+P338, P305+P354+P338, P308+P316, P317, P318, P321, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 136 reports by companies from 21 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Reported as not meeting GHS hazard criteria per 1 of 136 reports by companies.；There are 20 notifications provided by 135 of 136 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Status: Active Update: 04-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24044

Amitriptyline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

IMAP assessments - 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride: Human health tier I assessment；IMAP assessments - 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, hydrochloride: Environment tier I assessment

Consider gastric lavage only if within one hour of a potentially fatal overdose. Give 50 grams of charcoal if within one hour of ingestion. Prolonged resuscitation may be successful in case of cardiac arrest. Give sodium bicarbonate in case of arrhythmias. (A311)

Some rare side effects include tinnitus, hypotension, mania, psychosis, heart block, arrhythmias, lip and mouth ulcers, extrapyramidal symptoms, depression, and hepatic toxicity.Amitriptyline exhibits strong anticholinergic activity, cardiovascular effects including orthostatic hypotension, changes in heart rhythm and conduction, and a lowering of the seizure threshold (A308, L1032).

Amitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.

Symptoms of overdose include abnormally low blood pressure, confusion, convulsions, dilated pupils and other eye problems, disturbed concentration, drowsiness, hallucinations, impaired heart function, rapid or irregular heartbeat, reduced body temperature, stupor, and unresponsiveness or coma. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Amitriptyline hydrochloride

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Status: Active Update: 04-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24044

Amitriptyline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

Amitriptyline is rapidly and well absorbed following oral administration. Exclusively hepatic, with first pass effect. Amitriptyline is demethylated in the liver to its primary active metabolite, nortriptyline. Route of Elimination: Virtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with little unchanged drug appearing in the urine. 25-50% of a single orally administered dose is excreted in urine as inactive metabolites within 24 hours. Small amounts are excreted in feces via biliary elimination. Half Life: 10 to 50 hours, with an average of 15 hours

AMITRIPTYLINE HCL

Tricyclic Antidepressant [EPC]

AMITRIPTYLINE HYDROCHLORIDE

Tricyclic Antidepressant [EPC]

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.